A combination of growth hormone (GH) releasing peptides can lead to tremendous increases in GH levels, but such a process generally only requires a growth hormone releasing hormone (GHRH) analogue like sermorelin and a growth hormone secretagogue/ghrelin analogue like GHRP-2 or GHRP-6. Combining all three isn't likely to cause a proportionally greater increase in GH hormone levels, but there are other reasons to utilize such a combination.

Mechanism of Action

Mechanism of Action

This blend combines three peptides that target complementary GH-releasing pathways, producing synergistic amplification of pulsatile GH secretion while preserving the hypothalamic-pituitary feedback loop.

Sermorelin (GRF 1-29)

Sermorelin is the biologically active N-terminal 29-amino acid fragment of growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor (GHRHR), a class B GPCR on pituitary somatotrophs, activating the Gs/adenylyl cyclase/cAMP/PKA cascade. PKA phosphorylates L-type calcium channels and CREB transcription factor, simultaneously triggering acute GH release and stimulating GH gene transcription. Sermorelin preserves normal GH pulsatility and feedback regulation, unlike exogenous GH which suppresses endogenous production.

GHRP-6

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that activates the ghrelin receptor (GHS-R1a). This Gq-coupled receptor activates phospholipase C, generating IP3 (which mobilizes endoplasmic reticulum calcium stores) and diacylglycerol (which activates PKC). GHRP-6 also stimulates appetite through hypothalamic NPY/AgRP neurons and has mild cortisol and prolactin-releasing activity. Its GH-releasing effect is partially independent of GHRH, as it also suppresses somatostatin release.

GHRP-2

GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) is the most potent synthetic GHRP, with 2-3x the GH-releasing activity of GHRP-6 per unit dose. It has higher receptor affinity and more selective GHS-R1a activation with less orexigenic effect. GHRP-2 produces reliable GH release even in older subjects with declining GH output.

Synergistic Mechanism

The combination exploits dual signaling convergence on somatotroph calcium levels. Sermorelin-mediated cAMP/PKA signaling sensitizes voltage-gated calcium channels, while GHRP-mediated IP3/PKC signaling mobilizes intracellular calcium. The combined calcium signal produces GH exocytosis 3-5 fold greater than additive predictions. Additionally, GHRP-mediated somatostatin suppression extends the window during which GHRH can act, further amplifying GH pulse amplitude and duration.

IGF-1 Axis Activation

The amplified GH pulses stimulate hepatic IGF-1 production, which mediates the anabolic, tissue-repair, and metabolic effects of the blend. The preserved pulsatile pattern (vs. continuous GH exposure) preferentially activates the growth-promoting STAT5b signaling pathway and avoids GH resistance that occurs with constant receptor stimulation.

Reconstitution Calculator

Safety Profile

Safety Profile: Sermorelin / GHRP-6 / GHRP-2 Blend

Common Side Effects

• Injection site reactions: redness, swelling, pain, and itching at the subcutaneous injection site (very common with all three peptides)
• Facial flushing and warmth sensation lasting 10–30 minutes post-injection
• Headache, particularly during the first 1–2 weeks of use
• Intense hunger: GHRP-6 is a potent ghrelin mimetic that significantly stimulates appetite; GHRP-2 has moderate appetite stimulation; the combination can cause pronounced hunger 15–30 minutes post-injection
• Water retention and mild peripheral edema
• Dizziness and lightheadedness
• Tingling and numbness in extremities (paresthesia)
• Joint stiffness

Serious Adverse Effects

• Cortisol elevation: GHRP-6 and GHRP-2 both stimulate ACTH and cortisol release; the combination amplifies this effect, potentially causing elevated cortisol, disrupted sleep architecture, and catabolism at higher doses
• Prolactin elevation: both GHRPs stimulate prolactin secretion; combined use may cause clinically significant hyperprolactinemia (gynecomastia, libido changes, menstrual irregularities)
• Insulin resistance: sustained GH elevation antagonizes insulin signaling; fasting glucose elevations possible, especially in pre-diabetic individuals
• Carpal tunnel syndrome: IGF-1–mediated tissue edema may compress the median nerve at higher cumulative GH output
• Tumor promotion: GH/IGF-1 axis stimulation is a recognized proliferative risk factor for pre-existing malignancies
• Unknown long-term safety: this specific triple blend has no clinical trial data; safety is extrapolated from individual components

Contraindications

• Active malignancy or history of hormone-sensitive cancer
• Uncontrolled diabetes or diabetic retinopathy
• Active pituitary pathology
• Pregnancy or lactation
• Age under 25 (open growth plates)
• Hypersensitivity to any component peptide
• Active Cushing's syndrome or hyperprolactinemia

Drug Interactions

• Insulin and oral hypoglycemics: GH-mediated insulin resistance may require increased antidiabetic medication doses
• Glucocorticoids: may suppress endogenous GH release and counteract sermorelin efficacy; GHRP cortisol stimulation adds complexity
• Thyroid hormones: GH increases T4-to-T3 conversion; may alter levothyroxine requirements
• Dopamine agonists (cabergoline, bromocriptine): may partially counteract GHRP-induced prolactin elevation
• Somatostatin analogs (octreotide): directly antagonize GHRH signaling; negate sermorelin effects

Population-Specific Considerations

• Regulatory status: none of these peptides in combination is FDA-approved; all use is experimental; compounding pharmacy quality varies significantly
• Anti-aging population: primary demographic; the triple blend aims to maximize GH pulse amplitude via GHRH + GHRP synergy; requires disciplined monitoring
• Athletes: all three peptides are WADA-prohibited substances
• Monitoring: IGF-1, fasting glucose, HbA1c, cortisol (AM), prolactin, and thyroid panel should be checked at baseline and every 8–12 weeks
• Women: may require lower doses; more sensitive to water retention and prolactin elevation

Pharmacokinetic Profile